At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 83 enrolled
Drug / intervention
Fulvestrantdrug
Likely dose
Fulvestrant 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
In Brief
A Phase 4 clinical trial evaluating Fulvestrant for Locally Advanced or and Metastatic Breast Cancer. Completed, enrolled 83 participants across 9 sites.
Detailed Summary
This single-arm study aims to assess the safety and tolerability profile of Fulvestrant(Faslodex®) as 2nd line and later therapy in postmenopausal women with locally advanced or metastatic breast cancer. The primary objective is to evaluate the adverse events after Fulvestrant (Faslodex®) for about 6 months
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced or, Metastatic Breast Cancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartMay 2015
Primary CompletionMay 2016
Study CompletionSep 2020
TodayJul 2026
First PostedMay 18, 2015
Enrollment StartMay 29, 2015
Primary CompletionMay 6, 2016
Study CompletionSep 16, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.1 years ago
Interventions
Fulvestrantdrug
fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.